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Abstract: The European Lead Factory (ELF) is a unique collaborative public–private partnership aiming to deliver in-
novative drug discovery starting points and improving the value generated by ultra-High Throughput Screening (uHTS) 
approaches. Composed of a unique compound collection derived from private pharmaceutical company collections and 
complemented with new chemistries from a unique public collection, it offers a unique uHTS platform accessible to 
both private companies and publicly funded researchers. One of the key challenges in setting up ELF has been to bal-
ance access to screening results with protecting the value of compounds in the collection. Through an ‘honest data bro-
ker’ data management platform and a royalty reward scheme based on achieved milestones, ELF has been able to over-
come these challenges. Set up in 2013, it has already accepted 42 targets for screening, submitted by publicly funded 
researchers, and generated 12 Qualified Hit Lists. In addition, 55,000 new library compounds have been generated by 
the public partners and added to the 320,000 compounds made available by the companies. Although it faced many 
challenges in becoming operational, this unique experiment in collaboration is already generating exciting results that 
will hopefully, eventually lead to better medicines and tools to advance our biological knowledge, and should act as a 
template for future approaches in the area.  
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1. Introduction 
espite heavy investments into basic and app-
lied pharmaceutical research and steadily in-
creasing public and private efforts, sympto-
matic and more importantly, curative treatments are 
still only available for a limited number of known 
diseases. In nearly all indication areas, the unmet  
medical need is still enormous[1]. Progress is being 
made in pharmaceutical research, promising new tools 
and technologies are being integrated into discovery 
processes and our understanding of what is going on 
at the molecular level is growing. Yet even in this 
post-genomic era, human biology continues to reveal 
itself as highly complex and the overall success rate in 
drug discovery remains low[2,3]. Therefore, if we are to  
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discover new medicines and reduce R&D costs, new 
avenues and approaches to sharing risks and to reduc-
ing attrition rates continue to be of high interest to the 
pharmaceutical industry, healthcare systems and, most 
importantly, patients.  
One approach that appeared to offer a rapid route to 
helping understand the complexity of drug targets and 
accelerate the development of new medicines has been 
High Throughput Screening (HTS). However, whilst 
HTS approaches have matured and become an integral 
part of pharmaceutical research and a cornerstone in 
the expansion of biomedical knowledge, it has been 
blamed for failing to provide enough viable leads for 
many targets. The quality of existing compound col-
lections has often been cited as a reason for the poor 
quality of hits identified in many HTS campaigns[3,4]. 
Yet, the challenges faced by HTS extend beyond the 
quality of existing compound libraries. Corporate 
compound collections are still heavily safeguarded by 
pharmaceutical companies and consequently tested 
against only a fraction of disease-relevant targets de-
termined by a company’s therapeutic areas of interest. 
Furthermore, individual collections provide insuffi-
cient coverage of the ‘drug-like’ chemical space and a 
comprehensive comparison of the underlying library 
design strategies is hampered by company bounda-
ries[4,5]. As a result, within the existing competitive 
framework of safeguarded company compound col-
lections, their corresponding value[6,7] remains incom-
pletely realized. 
Therefore, if we are to accelerate the discovery of 
new drugs to benefit patients, we face a challenge in 
harnessing the true potential of HTS approaches and 
the untapped value in company collections, and in 
building platforms that allow wider access to unique 
compound collections for both competing companies 
and public entities alike. Against this backdrop of 
sharing collections, we must also find ways to protect 
the rights of the organisations and security of the 
compound collections involved, while allowing the 
exploitation of new research results in the form of new 
drug discovery programmes. 
In the following article, we describe a unique pub-
lic–private partnership called the European Lead Fac-
tory (ELF, see Supplementary information S1). ELF 
aims to address the challenge of delivering innovative 
ideas and to improve both the quality and value of the 
hits generated via HTS approaches. It is composed of 
the European Screening Centre (ESC) and the Joint 
European Compound Library (JECL). More than 
300,000 optimised industrial research compounds have 
been contributed by seven pharmaceutical companies 
to the JECL. These compounds from the companies 
are complemented by an all-new compound collection, 
based on designs and syntheses by small and me-
dium-sized enterprises (SMEs) and academic institu-
tions. The goal is to build a unique compound collec-
tion, unprecedented in current drug discovery plat-
forms, of up to half a million compounds. Screening 
of such compounds to assess their biological activity 
is also funded and performed by ELF for both private 
companies and selected public targets. This means 
substantial cost savings for contributors as well as a 
very productive exchange of ideas. State-of-the-art 
facilities are provided by the newly-established ESC, 
based in Scotland, Holland and England. The ELF 
project aims to run up to 240 screens, with third party 
drug target owners from academia or biotech ac-
counting for up to 120 of the screens.  
The ultimate deliverable by ELF is a list of ≤50 
well-characterised HTS hit structures, assembled in a 
so-called Qualified Hit List (QHL), which is provided 
to the owner of the related drug target to exploit and 
develop new drug discovery programmes. Crowd-
sourced drug target owners can benefit from medicinal 
chemistry services, including e.g. hit expansion, crys-
tallography and early “absorption, distribution, me-
tabolism, and excretion” (ADME) studies, to identify 
new tool compounds to enhance biological knowledge 
or even to further increase the chances of identifying 
lead compounds that can enter drug development 
phases. ELF provides researchers with a unique op-
portunity to screen their innovative targets against 
JECL, use the results to foster their research and sci-
ence, and enter into novel collaborative drug discov-
ery projects with EFPIA partner companies. 
In order to achieve its goals, ELF is supported by a 
substantial financial investment of 200 million euros 
shared by participating partners and Innovative Medi-
cines Initiative (IMI), clearly demonstrating that both 
public and private parties are strongly committed to 
the project. It differs from numerous previous aca-
demic initiatives in this field by emphasizing the as-
pect of value generation from its screening activities. 
The legal framework that underpins ELF promotes the 
generation of new IP, while encouraging knowledge 
sharing through dissemination of results and ensuring 
that the interests of all participating parties are re-
spected. While publication of results is facilitated and 
welcomed, publications alone are not viewed as a key 
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measure of success. More tangible value is seen in the 
exploitation of results to realise their value, whether 
this be through downstream alliances formed to pro-
gress the screening results along the pharmaceutical 
value chain, license agreements around generated in-
tellectual property or the generation of spin-outs based 
on assets that originated from external contributors 
and ELF.   
2. Why are Pharmaceutical Companies In-
volved in ELF? 
In response to the increasing challenges faced in drug 
discovery, large pharmaceutical companies have real-
ized that internal resources are no longer sufficient to 
increase R&D productivity and, in response, have be-
gun to intensively search for and integrate external 
innovation[9]. In the search for novel models and 
strategies, open innovation and crowdsourcing initia-
tives have attracted tremendous interest from pharma-
ceutical companies and public institutions in the last 
decade[10,11]. The transfer and exchange of knowledge 
between the private and public sector, and on a pre-
competitive level between pharmaceutical companies, 
seems to be the current remedy of choice. This zeal to 
source external innovation has many merits as a 
higher number of partnerships, genuine collaborations 
and extended networks will help to cover a much 
broader span of research across the available chemical 
and pharmacological universe. By no longer operating 
in isolation but synergizing activities instead, both 
academia and pharma will benefit by avoiding dupli-
cation of effort and being able to make quicker pro-
gress based on more, better quality data. Greater value 
generation should be a natural consequence for the 
companies and public institutions that engage in these 
collaborations, ultimately benefiting patients. Positive 
experiences from the recent past indicate that particu-
larly in the early high risk phases of drug discovery 
different stakeholders can strongly profit by collabo-
rating with each other[9,12–14].  
At the end of 2012, seven pharmaceutical com-
panies committed to participating in ELF. Both the 
opportunity to screen against the unique JECL with 
300,000 compounds contributed by the pharmaceuti-
cal companies complemented by public library pro-
grams as well as the prospect of building partnerships 
with third parties providing targets that are screened at 
the ESC constitutes an attractive value proposition. 
With respect to the latter, ELF helps to translate early 
research into drug discovery programmes, i.e. ena-
bling the identification of high quality hits that can be 
eventually developed into lead compounds and ulti-
mately, drugs or diagnostic chemical tools. Bringing 
together excellence in synthetic organic chemistry, 
screening and logistics expertise, and drug discovery 
know-how, embedded in a clear legal framework en-
sures that ELF can achieve its objectives. In summary, 
the consortium platform represents an excellent avenue 
for companies to initiate, promote and foster collabo-
rations on the next generation of exciting innovative 
drug discovery projects. 
Another important element in facilitating compa-
nies to collaborate in such a commercially sensitive 
area is ensuring that IP is protected. As ELF allows 
different companies to access their competitors’ com-
pound libraries, clear data and management processes 
supported by robust IT tools are mandatory to prop-
erly protect the intellectual property of all parties par-
ticipating in ELF. This is accomplished within ELF by 
means of an Honest Data Broker (HDB), ensuring that 
the compounds in the composite library remain hidden 
from individual partners, thus maximizing security. 
ELF allows a company’s targets to be screened against 
chemotypes that only exist outside of an individual 
company’s library, hence maximizing the opportunity 
to find potentially interesting compounds and increas-
ing the chance of identifying successful hits[15]. The 
importance of the HDB system should not be underes-
timated in facilitating the involvement of normally 
competitive companies in this type of programme. 
3. The European Screening Centre 
3.1 Generation of Qualified Hit Lists 
(1) Operations: The screening activities of ELF take 
place at eight screening centres, one each for the seven 
participating European Federation of Pharmaceutical 
Industries and Associations (EFPIA) companies and 
the last at the ESC (described in supplementary in-
formation 1, S1), where the crowdsourced public drug 
targets are screened. The drug targets screened at the 
ESC are sourced from researchers at European aca-
demic organisations and SMEs. A target programme is 
defined as a combination of a defined molecular target 
identified by its unique gene ID and a mode of com-
pound action, i.e. agonist, antagonist, inhibitor, or en-
hancer. The submitted target proposals are selected 
based on a number of scientific and technical criteria 
(Tables 1 and 2) and evaluated by experts from the 
consortium and independent external reviewers in the 
Screening Selection Committee.  
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Table 1. Target Proposal Criteria 
Criterion Defined by 
Scientific value 
 
 
 
 
 
• Scientific quality 
• Innovation potential of target  
or  
new chemistry associated with target 
• Disease relevance 
• Diversity of portfolio 
Different from EU Lead Factory targets 
 
 
• UniProt ID  
• Entrez Gene ID and 
• Mode of compound action 
Technical feasibility of the assay The screening assay requirements in Table 2 
Transfer to HTS in 3˗4 months The screening assay requirements in Table 2 
 
Table 2. Screening Assay Requirements 
Characteristic Requirement 
Assay format Demonstrated in 384-well plate format, preferably scalable to 1536-well plate format 
Homogenous assay  No wash steps 
Characterised reference  Available from partner or commercially available 
Readout technology 
 
 
 
 
 
 
 
 
 
Compatible with mix-and-measure and homogenous formats, e.g.:  
• Absorbance 
• Luminescence 
• Fluorescence intensity 
• Fluorescence polarization 
• Fluorescence resonance energy transfer (FRET) 
• Time resolved fluorescence (TRF) 
• Homogeneous Time Resolved Fluorescence (HTREF) 
Or alternatives that give highly specific readouts (e.g. AlphaScreen technology, fluores-
cence lifetime, fragment complementation or FLIPR for calcium readout) 
Signal / Background (S/B) 
in 384-well plate format, max assay end volume 30 
µL, sample end concentration 10-5 mol/L 
> 3; preferably higher  
/ high control signalS B
low control signal
=   
Z' (Z prime) in 384-well format, max assay end volume 
30 µL, sample end concentration 10-5 mol/L 
 
> 0.6 
3( . . . . )1
( )
s d high control s d low controlZ
mean high control meanlow control
+′ = −
−
 
DMSO tolerance  Minimal tolerance 0.5% DMSO 
Stability of each reagent 
 
Stable for at least 8 hours 
For proteins: proven freeze–thaw cycle stability 
Cell lines  
 
Certified Mycoplasma free  
Stable cell lines 
Minimal signal pattern on plates CV <10% across plate filled with reference compounds 
Protein  
 
Recombinant protein at least 80% pure 
Commercially available or feasible to produce on milligram scale 
Incubation times Up to 4 hours 
Readout stability For at least 1 hour 
Experimental data 
 
All existing data relating to assay development will be shared. A minimum data package at 
least shows that the technical specifications are met. 
 
Once a target programme is accepted, a programme 
team is formed by the target owner and experts from 
the ESC, who write a comprehensive plan defining the 
strategy to the retrieve the best (≤50) hits i.e., the 
Qualified Hit List (QHL). All programmes follow the 
same workflow, described in Figure 1. Once a QHL is 
generated, the recipient is granted exclusive rights to 
the compounds on the list, which are from then on 
excluded from the screening collection. In order to not 
deplete the quality of the subsequent QHLs, a target 
programme can only be accepted and screened once. 
In addition, for most programmes, post-QHL work is 
done to further validate the initial hit structures and 
derive structure activity relationships (SARs) of hits 
or hit series. Wherever possible, this work is sup-
ported by structural data from protein crystallography. 
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Figure 1. Typical assay cascade for a target programme to move from the original screening results to the generation of an Improved 
Hit List. 
 
(2) Assets: The target programme can benefit from 
some of the most advanced compound management 
and screening capabilities of Europe, based on the 
legacy of the Merck, Sharpe & Dohme research sites. 
The JECL compounds are stored in single use tubes, 
minimizing freeze–thaw cycles, in a controlled at-
mosphere at low temperature, minimizing decomposi-
tion. In addition, the technology used allows cherry- 
picking of any combination of samples and plating 
them in a wide variety of formats, providing rapid 
access to precise libraries of follow-up samples. The 
ESC screening activities are state-of-the-art within a 
ultra-HTS (uHTS) laboratory running bioassays of all 
the most common read-out methodologies (e.g. lumi-
nescence, fluorescence, fluorescence polarization, 
FRET, FRETTR, alphascreen, luciferase, β-lactamase 
activity and complementation, and FLIPR assay tech-
nology) in either 384- or 1536-well plates. Comple-
mentary to this are the protein production and crystal-
lography groups at the University of Oxford associ-
ated with Structural Genomics Consortium (SGC) 
with a world-leading record of producing high-reso-
lution crystal protein–ligand structures.  
(3) Screening cascade: The typical outline of the 
screening and triaging campaign is shown in Figure 2. 
After transfer of the assay and materials from the pro-
gramme owner to the ESC, assay development can 
start, including miniaturization, optimization for the 
HTS platform, assay robustness tests and, if necessary, 
development of deselection/orthogonal assays. If the 
amount of protein needed for an HTS campaign can-
not be produced by the programme owner, the team at 
the University of Oxford can be involved. uHTS is 
followed by confirmation of identified actives from 
the screen by retesting at single-point concentrations 
and later generation of dose-response curves using the 
primary assay conditions. False positives are elimi-
nated by testing the primary hits in at least one dese-
lection or orthogonal assay. Biophysical technologies 
such as Surface Plasmon Resonance (SPR) and Mi-
croscale Thermophoresis (MST) have proven particu-
larly useful in the triaging process. Various computa-
tional triaging tools are regularly applied to further 
refine the hits. At this point in the programme, a 
so-called Preliminary Hit List (PHL) is nominated and 
for the first time, structural formulae can be viewed, 
but only by a very limited number of people. The fact 
that only a small group of nominated individuals are 
able to see any JECL structures is an essential feature 
of the HDB system employed by the project. In order 
not to compromise the value of JECL and other future 
QHLs, the number of compounds on the PHL is lim-
ited to a maximum of 0.1% of the screening set (cur-
rently up to 350 compounds). Finally, a maximum of 
50 compounds are cherry-picked for the QHL based 
on the programme owner’s background knowledge 
and wishes as defined in the programme plan, analytic 
results (LC–MS), prioritisation on activity, visual in-
spection and clustering. 
To further add value to the target programme, the 
target owner and the programme team can opt to pur-
sue post-QHL work within ELF, leading to a so-called  
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Figure 2. Progress of public programmes submitted to the European Screening Centre. Progress is represented by the number of 
completed programmes at the respective stages in April 2015. 
 
Improved Hit List with QHL compound analogues. A 
bespoke medicinal chemistry programme in closer 
collaboration with the target programme owner is 
performed at the University of Dundee site in New-
house. The first steps often involve resynthesis and 
further characterisation of selected QHL compounds, 
followed by hit expansion to generate SARs. Thanks 
to the facilities at the University of Oxford, crystalli-
sation efforts can also be pursued for a limited number 
of programmes. 
3.2 Progress 
As of April 2015, a total of 42 public target proposals 
have been accepted by ELF from 74 submitted pro-
posals. Most proposals are sourced via the networks of 
people working in ELF, which is reflected in the geo-
graphical origin of both submitted and accepted pro-
posals (Figure 3). The majority of both submitted and 
accepted proposals originate from academic organisa-
tions (e.g. universities, medical centres and universi-
ties’ research institutes) while SMEs are the owners of 
the remaining quarter (see pie chart in Figure 4(A)). 
ELF aims to run programmes related to all human 
disease areas and all types of defined molecular tar-
gets. Compared to the analysis made in the US and 
UK[16,17], the addressed disease areas (Figure 4(B)) are 
rather similar, although oncology targets are overrep-  
 
 
Figure 3. Geographic distribution of accepted and submitted 
target proposals. 
 
resented in the current ELF portfolio. However, the-
type of drug targets (Figure 4(C)) are different. For 
example, a higher proportion of programmes targeting 
protein–protein interactions, a target family identified 
relatively recently and generally considered as associ-
ated with higher risks. 
To date, all programmes that have advanced to as-
say development have been successfully completed 
and all of them have been converted to run in 1536- 
well plate format and finished within 1–3 days. All av-
ailable technologies are represented in the completed 
screens. At the time of writing, a total of 12 QHL  
 
 
 
Figure 4. Character of drug target programmes accepted as of 15 April 2015. (A) Type of organisation submitting target proposals. 
(B) Main therapeutic area addressed by accepted programmes. (C) Nature of molecular drug target. 
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reports have been written. The associated QHLs include 
3–50 compounds with a median of 46 compounds. 
The compounds represent not only a high fraction of 
different chemotypes reflected in the relatively many 
singletons (19 in average), but also clustered com-
pounds from which a budding SAR can be deduced. 
The QHLs were selected by applying 3–7 different 
assays for most of which dose–response curves were 
generated as part of the triaging process. Such exten-
sive and in many cases labour-intensive post-HTS 
characterisation of hits takes time, on average 165 
days but ranging from 40–271 days depending on for 
example the complexity, maturity and number of as-
says implemented, as well as the availability of the 
screening materials needed. In several cases, bespoke 
assays have been developed in the course of the pro-
gramme. Additionally, computational models, e.g. 
Bayesian models, have been used in all 12 pro-
grammes to identify not only false positives, but also 
false negatives. Post-QHL/IHL work is currently go-
ing on for seven programmes at different stages. The 
most advanced ones have provided their programme 
owners single-digit nanomolar or even picomolar 
ligands and several protein–ligand crystal structures 
have been resolved. 
As screening of the compounds synthesised within 
ELF began in February 2015, all QHL compounds so 
far originate from the EFPIA companies. The distribu-
tion over the different sub-collections is very even. 
Interestingly, compound clusters are in several cases 
composed of compounds from more than one com-
pany, highlighting another advantages of pooling 
screening collections[15].  
3.3 Challenges  
It should be admitted that the consortium undertook 
the crowdsourcing task with a certain naivety. Project 
partners were convinced that the attractiveness of the 
incomparable facilities and services offered to the 
European research community with no upfront costs 
would result in a number of expected proposals far 
exceeding the actual submissions in the first two years. 
Feedback has shown that one of the biggest hurdles 
for an applicant is the key quality constraints on ac-
cepted target assays e.g., proven reproducibility in 
384-well plate format. Needless to say, meeting this 
requirement is a great challenge for many routinely 
used research assays. Another challenge relates to the 
accession process. Although the proposal submission 
form is rather brief, the length and complexity of the 
legal framework can have a discouraging effect, par-
ticularly for academics who would rather focus their 
attention on their research. However, the correct legal 
framework is pivotal for any collaboration that wishes 
to bring new drugs to patients. On the one hand, the 
need to balance protecting IP, with allowing different 
partners access to data to ensure that new compounds 
can be progressed through development. On the other 
hand, it is recognised as a challenge in all forms of 
collaboration, equally for both public and private 
partners. How ELF attempts to find the delicate bal-
ance required in this area is further discussed in a later 
section. 
For many programmes, the post-HTS screening 
cascade has also posed problems. The identification 
and development of relevant deselection and orthogo-
nal assays were perhaps not stressed enough in the 
information given to the target owners in the first 
crowdsourcing calls. For some target classes, several 
approaches to identify relevant and validated hits can 
be applied and these have to be agreed upon, slowing 
down the process for individual targets.  
4. The ELF Chemistry Consortium 
A second, equally important asset of ELF is its com-
pound collection—the JECL. At the outset of the pro-
ject, around 320,000 high quality compounds were 
contributed by the pharmaceutical companies within 
the consortium[15]. However, a key project goal for the 
ELF Chemistry Consortium is to complement these 
compounds with up to an additional 200,000 com-
pounds during the project timeline. JECL is therefore 
a unique resource not available anywhere else in the 
world. The ELF Chemistry Consortium offers a 
unique blend of European chemistry expertise from 6 
SMEs and 10 academic centres (described in S1). To-
gether, these 16 partners are tasked with the design, 
validation and production of the libraries building the 
Public Compound Collection (PCC), according to the 
workflow detailed below and summarized in Figure 5. 
4.1 Ensuring the Quality and Novelty of Com-
pounds in the Public Compound Collection 
The additional 200,000 JECL compounds offer the 
opportunity to explore new chemical spaces that are 
not commercially available and typically not ad-
dressed in traditional screening collections from 
chemical vendors or corporate EFPIA collections. 
This new compound collection is based on proposals 
that are submitted by academic or industrial chemists— 
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Figure 5. Compound Library workflow in the ELF Chemistry Consortium: key aspects of the various steps are highlighted. 
 
from either within or without the consortium—using a 
step-by-step procedure via a web-based tool. Mone-
tary incentives in the form of grants are awarded to 
external contributors, based on the maturity level of 
the submitted library proposals. More importantly, 
when submitting library proposals to ELF, the external 
contributors retain the right to publish their own re-
search and findings. Submitted library proposals are 
assessed by an eight-strong Library Selection Com-
mittee (LSC) of respected chemists from EFPIA, 
SMEs and academia, all bound by confidentiality, to 
provide broad and complementary chemistry and drug 
discovery expertise. The data and information pro-
vided at a library proposal stage is used to assess the 
original design against 6 specific criteria: novelty, 
molecular properties, synthetic tractability, diversity 
potential, structural features and innovative library 
design. Importantly, each submitted library proposal 
should have a high element of novelty. This is rou-
tinely assessed by comparing the proposed library 
scaffold and enumerated matrix against the existing 
JECL collection and already submitted JECL libraries, 
commercial vendor sources (http://emolecules.com/) 
and additional chemistry-based compound reposito-
ries[18–21]. Furthermore, molecular properties and 
structural features should be preferably aligned to 
contemporary hit- and lead-like properties (e.g. calcu-
lated log P less than 4) to ensure a high ratio of solu-
ble compounds at typical screening concentrations in 
primary target-based HTS assays[22]. Deviations from 
such properties are considered especially when a 
strong design concept (e.g. natural product inspiration, 
target class focus) is provided. Another often under-
appreciated aspect of library design is practical im-
plementation. The LSC also evaluates the feasibility 
of submitted library proposals in terms of the subse-
quent reduction to practice. Here, aspects such as cost 
of goods, atom economy, length and efficiency of the 
synthetic route, associated purification and diversifi-
cation steps are all accounted for based on the infor-
mation provided by the submitter and the LSC mem-
bers’ experience. 
The feasibility of selected proposals is then deter-
mined experimentally by academic and industrial 
consortium partners. During this stage, pilot projects 
are initiated to verify whether the intended libraries 
can be effectively produced within the ELF project 
timeline and budget. The focus of these library valida-
tion activities is to establish optimal conditions for 
critical synthetic and purification steps, and provide 
experimental proof that these can be carried out on the 
scale required for the production of the compound 
library. Another critical aspect of library validation in 
the ELF Chemistry Consortium is the definition of the 
reagent scope for each of the intended diversity points 
in a library. Here, by sampling a subset of available 
building blocks from the reactivity and physico-
chemical properties standpoints, valuable information 
about the accessible library diversity is generated. The 
new ELF libraries that have been successfully vali-
dated are then produced in their entirety by the indus-
trial consortium partners. Modifications to the original 
design based on diversity and practical considerations, 
as from the library validation stage, are incorporated 
into the final library blueprint. The validated synthetic 
protocol is then executed to standard industrial speci-
fications. Final compounds meeting JECL quality cri-
teria for purity (LC–MS purity >85%) and quantity 
(>5 µmol) are added to JECL.  
4.2 Managing the Process and Progress to Date 
Given the size and heterogeneity of the ELF consor-
tium, chemistry project management is critical to suc-
cess. Real-time monitoring and decision-making is 
enabled by TarosGate, an informatics platform devel-
oped by the consortium coordinator Taros, which 
seamlessly connects the chemistry laboratories of the 
sixteen academic and SME partners. Rapid evaluation 
of progress and productivity with TarosGate has given 
the ELF chemistry consortium a flying start. Since the 
recruitment of scientists was completed and synthesis 
started in late 2013, an efficient pipeline leading to the 
addition of distinctive screening compounds to the 
JECL has been established. By the end of March 2015, 
564 library proposals had been submitted and 385 of 
these had been accepted for synthetic validation, 
equating to a 69% success rate, of which 120 had been 
successfully validated experimentally. Forty nine of 
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the submitted library proposals were terminated based 
on technical failure during validation yielding a 29% 
attrition rate for that phase. The end result of this effi-
cient process is that more than 55,000 screening 
compounds had been produced for addition to the 
JECL, as summarized in Table 3. 
 
Table 3. ELF Chemistry Consortium progress as defined by the 
number of chemical libraries at different phases of the chemical 
library selection and validation process. The success rate at 
each phase is indicated as a percentage in brackets. All figures 
correct as of 31 March 2015. 
Library  
Proposals 
Accepted 
Library  
Proposals 
Libraries 
Validated 
Successfully 
Validated  
Libraries 
Failed  
Libraries 
564 385 (69%) 169 120 (71%) 49 (29%) 
 
4.3 Challenges 
During the past year and a half of work in the ELF 
Chemistry Consortium, the foundation for the suc-
cessful implementation of an innovative compound 
library factory has been laid. In true collaborative 
spirit, the chemistry partners have been learning from 
each other’s strengths and expertise and understanding 
the different chemistry perspectives of leading aca-
demic laboratories and pragmatic SMEs. This, to-
gether with the persistent focus on quality, has enabled 
the ELF Chemistry Consortium to improve its success 
rate at library selection stage from an initial low of 30% 
to 69% today. Not surprisingly, library validation still 
represents the most challenging aspect of compound 
library production for screening purposes. Here, the 
current 29% attrition rate is still very much in line 
with industry averages, highlighting once again how 
critical experimental investigations are and how elusive 
progress in chemistry research can be. Here, a key 
lesson is to establish a rigorous progress evaluation 
mechanism to minimize work in progress, and focus 
resources on key experiments and decision points. As 
a rule of thumb, if significant progress or problem 
resolution in an ELF library validation campaign is 
not achieved within 8 weeks, then scientists and man-
agers should seriously consider project termination. 
An additional challenge faced by the ELF Chemis-
try Consortium is the engagement of the wider chem-
istry community in the submission of creative library 
proposals. This may still reflect the historical reluc-
tance to share chemistry, especially for drug discovery 
applications, due to the immediate relevance to intel-
lectual property (IP) and value creation. We neverthe-
less trust that the transparent process established by 
the ELF consortium in handling IP, owner’s rights and 
responsibilities plus the monetary incentives allocated 
for submitters can open up opportunities for chemists 
of any experience level and affiliation to more actively 
contribute to it, as a way to further enhance the reach 
and impact of their research. 
These challenges notwithstanding, the scientists of 
ELF Chemistry Consortium have developed key ap-
proaches that can facilitate novel bioactive molecule 
discovery, including diversity-oriented synthesis, bi-
ology-oriented synthesis, multicomponent chemistry 
and activity-directed synthesis, as recently described 
for selected examples[23–34]. The innovative chemical 
approaches taken by the ELF Chemistry Consortium 
are yielding novel, diverse and distinctive compounds 
that will complement existing large compound collec-
tions used for high throughput screening drug discov-
ery applications, thus serving as a blueprint for future 
compound collection enhancement campaigns. 
5. The Challenges of Data Management, IP 
and Access Rights 
The building of such an ambitious drug discovery 
platform based on novel drug target screens against 
such a large-scale compound library, composed of 
compounds from diverse protected sources, has led to 
some specific data management and legal challenges. 
While the ELF project is based on the collective effort 
of a range of pharmaceutical companies, it also aims 
to collect more biology targets and chemistry scaffolds 
from SMEs and academic groups either participating 
directly in the project, or contributing to it as external 
third parties. A key challenge has been to achieve the 
right legal approach among the partners in order to 
ensure the protection of their respective valuable as-
sets while enabling the exploitation of the outputs 
from the screening activities. To build a consortium 
with 30 participants and, for now, around 30 external 
partners, all contributing with potentially patentable 
information and safely sharing chemical, biochemical 
and biological data is complex. The need for a data 
management platform that would enable the uploading 
of data and use of various triaging tools, yet prevent 
information leakage that could compromise future IP, 
was identified at an early stage. HDB has been devel-
oped by BIOVIA using the HEOS/ScienceCloud plat-
form and has been up and running since May 2014. 
The functionalities it provides at this stage are out-
lined in Figure 6.  
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Figure 6. Functions enabled by the bespoke database: the Honest Data Broker. 
 
A second challenge has been to design a suffi-
ciently attractive scheme to encourage potential ex-
ternal compound and target owners to participate. In 
this context, the ELF partners rightly considered the 
need to address the IP framework during their negotia-
tions as early as possible. This brought with it the 
added challenge of facilitating discussions between 
the scientific and legal/IP communities not only within 
each organisation but also between the partners. ELF 
partners acknowledged that a set of basic rules was 
required and the IMI Intellectual Property legal 
framework, based on open source collaboration, pro-
vides consortium-specific yet flexible working rules, 
allowing the partners to agree on the basic principles 
for the most appropriate agreement(s) considering the 
objective of the project and the legitimate interest of 
each participant. 
It is also important to remember that participating 
in an IMI project does not affect the initial IP owner-
ship regime. By submitting a chemistry compound or 
chemical scaffold, each owner is guaranteed the abil-
ity to retain the original ownership of its pre-existing 
know-how brought into the project (while this is re-
ferred to as background in the IMI IP policy, such 
pre-existing know-how may or may not be covered by 
IP measures). However, it is also known from the start 
that the partners will also get access to this “back-
ground”, on a royalty-free basis for project completion, 
on fair and reasonable terms for any further research 
and development activities or use, and on conditions 
to be agreed for commercialisation and exploitation 
purposes. A mirror approach is also applicable to ex-
ternal contributors, meaning that the ELF consortium 
partners have agreed to treat direct and indirect part-
ners equally from the outset. 
In terms of the IP ownership of results arising from 
the project, a central question was how to manage the 
value to be generated during the project (referred to as 
“foreground” in the IMI IP policy). The objective was 
not only to protect the initial asset of the owner(s) but 
also to reward the scientific and intellectual contribu-
tions of other partners. As a basic principle, ownership 
of the foreground belongs in the first instance to the 
participant(s) who generated it. However, the partici-
pants may agree before work commences on a differ-
ent allocation of ownership. ELF partners agreed on 
taking full advantage of the flexibility offered by the 
IMI IP policy and due to the constant close interaction 
between the drug target programme owners and the 
consortium partners, a complex joint ownership model 
was developed especially to accommodate those ex-
ternal contributors. Once again, with the view of at-
tracting external ideas into the project, all target own-
ers whether they are external third parties or members 
of the consortium abide by the same set of rules and 
are treated equally. 
Another element of complexity arises from the fact 
that the IMI IP policy provides for any third party, 
contributing or not, with the opportunity to request 
access to the foreground generated by the ELF part-
ners as long as they are related to a consortium partner. 
This is a challenge in a project in which the entities 
contributing chemical compounds need to protect the 
IP around these compounds so that their value is 
maintained. It was therefore very important that the 
definition of fair and reasonable conditions for access 
to data that could be used for further research and de-
velopment uses was correctly formulated, respected 
all parties’ interests and was acceptable to all parties. 
To that end, a reward scheme was agreed upon for 
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both internal and external library design contributors 
to which non-contributing third parties have limited 
access, the entire process being transparently de-
scribed on the ELF website[35]. However, experience 
to date has shown that the complexity of this interest-
ing reward scheme has made communication with the 
external scientific community difficult and is hinder-
ing the engagement of some external parties with the 
project. The existing communication campaign re-
garding the rights and obligations of both the drug 
target and library design contributors provides clear 
and transparent advice, but the process to formalise 
the various legal and official agreements to create the 
binding components is an ongoing challenge. 
An attractive dissemination policy is also necessary 
to convince a wide range of stakeholders to participate. 
A key element of any research agreement entered into 
by an academic will be the right to publish the result, 
for example, in the form of scientific papers and to use 
the results in connection with teaching, academic re-
search and grant applications. In the case of ELF, 
however, the partners can prevent premature publica-
tion which may infringe the IP rights and their exploi-
tation potential. Ultimately, the goal of the ELF pro-
ject is to find valuable lead structures that might have 
previously been inaccessible—structures that could 
result in the development of novel treatment options 
for patients. To that end, appropriate confidentiality 
and protection measures have been put in place in the 
context of allowing value generation from the results 
of screens and JECL compound generation. However, 
in order to facilitate dissemination, the ELF partners 
agreed to review proposals for publication and/or de-
lay publication by a reasonable period of time during 
which IP can be sought or subject to licensing agree-
ment for commercialization purposes. In addition, 
rejection of a publication request can only be made on 
a few well-defined grounds. 
In an attempt to balance the sometimes conflicting 
demands of value generation and dissemination of 
research results, items such as IP management, access 
rights and publication of results have proven to be 
some of the most difficult challenges of ELF. The 
current legal agreements covering targets and chemis-
tries constitute a balanced approach and have allowed 
the project partners to make rapid progress towards 
achieving the overall objectives of the project. How-
ever they are the result of compromises made by each 
of the partners to ensure that the project can function 
and achieve its ultimate objectives. The legal frame-
work has also helped to build trust within the consor-
tium across a very diverse set of partners. As such the 
current legal framework has already served as a tem-
plate for other IMI projects (e.g. within the antimicro-
bial resistance programme or for the European Alz-
heimer platform) and could provide a fair and equita-
ble approach for future collaborative drug discovery 
research. 
6. Conclusion 
Although shared platforms for pooling HTS resources 
and approaches have been tried before and success-
fully generated interesting lead molecules and chemi-
cal probes[36], ELF is a unique initiative in that it is 
attempting to deliver not just interesting compounds 
that may result in lead molecules for drug discovery, 
but real value propositions that can be exploited by 
public and private partners alike from the outset. The 
construction of this unique platform has faced many 
challenges, some of which have been discussed in this 
article. All of these are being addressed through a 
combination of hard work and scientific excellence, 
based on a strong foundation of trust and respect be-
tween all consortium partners, irrespective of their 
background. The management of such an initiative is 
no easy task, but the pace and amount of progress 
made in the past two years is a great achievement and 
reflects a strong, transparent management style. The 
development and instigation of the HDB, though often 
difficult, is central to the successful operation of ELF 
and serves as a model for future initiatives in the drug 
discovery area, particularly when protected assets are 
being leveraged on to generate value by different par-
ties. Now with the HDB operational, QHLs and IHLs 
are being delivered to public and private partners alike. 
The quality of these lists is also of a high standard as 
testified by a recent analysis and experience of target 
owners[35,37].  
An interesting aspect of ELF is that it provides a 
varied, yet centralized resource for early drug discov-
ery, offering advantages at both an operational and 
innovation level to public and private participants 
alike. For instance, by leveraging on a diverse and 
complementary consortium, one ensures a constant 
flow of different perspectives, ideas and solutions. 
Pooling resources and talents across different organi-
zations also yields better scalability to tackle problems 
and volumes that would be difficult to address by sin-
gle enterprises. Furthermore, the “factory” remit on 
the successful design and execution of scientific re-
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search generates cutting edge expertise and know-how 
in the various aspects of lead generation (e.g. library 
design and synthesis, assay development, HTS, 
hit-to-lead). Together these constitute important steps 
towards the establishment of ELF as a lead generation 
center of excellence. However, we still face challenges 
in establishing a sustainable future for this initiative 
and ensuring that the high quality results that are be-
ing generated are exploited to generate the maximum 
value as well as ensuring that the maximum benefit is 
felt by patients. 
From the outset, ELF was a novel approach to try 
and provide better quality leads for future drug dis-
covery programmes. In the first two years of its opera-
tion we have seen rapid progress in the establishment 
of its operations and are now beginning to see the 
production of high quality results. What was viewed 
by some as an interesting experiment in collaboration 
has already delivered on its potential and although 
many challenges remain and the road ahead may con-
tain many bumps and unexpected turns, ELF is un-
doubtedly a success and should act as a model for fu-
ture public–private partnerships in drug discovery.  
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Supplementary information S1 
The EU Lead Factory is an entirely new kind of part-
nership, between public and private organisations, 
designed to promote innovation by ensuring in-depth 
collaboration, honest brokerage and enhanced com-
munication. 
With 30 international partners and 150 employees, 
the EU Lead Factory capitalises on the innovation of 
academia, the agility of SMEs and the experience and 
resources of EFPIA members. 
The seven large pharmaceutical companies partici-
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pating are: Bayer, Janssen Pharmaceutica NV, Astra-
zeneca, H. Lundbeck A/S, Merck KGaA, Sanofi 
Aventis Deutschland GmbH and UCB Pharma SA 
The five partners of the European Screening Centre 
are Pivot Park Screening Centre (assay development 
and ultra-high-throughput screening (uHTS)), Univer-
sity of Oxford (protein production and structural bi-
ology), University of Dundee, Newhouse, (hit charac-
terisation and medicinal chemistry) BioAscent (com-
pound logistics) and TI Pharma (programme man-
agement) 
ELF Chemistry Consortium offers a unique blend 
of European chemistry expertise from 6 SMEs (Taros, 
Edelris, Lead Discovery Center, Mercachem, Syncom 
and Sygnature) and 10 academic centers (Max Planck 
Institute Dortmund, VU University Amsterdam, Neth-
erlands Cancer Institute, University of Duisburg-Essen, 
University of Groningen, University of Leiden, Uni-
versity of Leeds, University of Nijmegen, University 
of Nottingham and Technical University of Den-
mark).(https://www.europeanleadfactory.eu/). 
ELF is a unique collaboration between public and 
private entities under the Innovative Medicines Initia-
tive (IMI). Launched in 2008, the IMI has as its main 
objective the goal of significantly improving the effi-
ciency and effectiveness of the drug development 
process with the long-term aim that the pharmaceuti-
cal sector produces more effective and safer innova-
tive medicines. The IMI provides a platform where 
pharmaceutical industrial researchers, academic re-
searchers and other stakeholders can best participate 
in unique research collaborations and where several 
traditionally competing companies join forces. In its 
original guise the IMI’s budget of €2 billion for the 
period 2008–2013 made it the largest life sciences 
PPP in the world. Half of this budget came from the 
EU’s Seventh Framework Programme (FP7). The rest 
came in the form of in-kind contributions from EFPIA 
and its member companies. The IMI now continues as 
IMI 2, set up under Horizon 2020 and with a total 
budget of €3.3 billion for the period of 2014–2020. 
(http://www.imi.europa.eu/) 
 
